Skip to main content
Erschienen in: Molecular Neurodegeneration 1/2013

Open Access 01.09.2013 | Poster presentation

Tau-Hsp70 interaction on the single molecule level

verfasst von: Franziska Kundel, Magnus Kjaergaard, Sarah Shammas, Sophie Jackson, David Klenerman

Erschienen in: Molecular Neurodegeneration | Sonderheft 1/2013

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Background

As the protein quality control centre of the cell molecular chaperones tightly regulate amyloid proteins and seem to alleviate their cytotoxicity. However, the precise mechanism of this interplay and how its modification leads to disease remain elusive.
Particularly oligomeric species of amyloid proteins have emerged as the most important mediators of neurotoxicity in neurodegenerative diseases. However, these oligomers are exceedingly hard to characterize as they are transient, heterogeneous and rare relative to the monomeric and fibrillar states. We have developed single molecule FRET techniques for the time-resolved detection and characterisation of oligomeric species [13].
Here, we characterise the oligomers evolving during the aggregation of a tau variant carrying the Δ280K mutation associated with some forms of frontotemporal dementia. Further, we study the interaction of these oligomers with the intracellular chaperone Hsp70 which has previously been identified as a key regulator of tau turnover.

Materials and methods

We perform single-molecule FRET measurements for the detection of dual labelled tau oligomers. On a confocal setup two lasers of different wavelengths are overlapped to excite a sub-femtolitre confocal volume. The heparin induced tau oligomers at picomolar concentrations are flowed through the confocal volume using a microfluidic device and coincident fluorescent bursts of donor and receptor fluorophores are readily detected. Analysing the frequency and intensity of these bursts allows us to determine the amount and stoichiometries of the oligomers.

Results

Δ280K tau oligomerisation is rapid with a maximum number of oligomers observed approximately 45 minutes after heparin induction.
In the presence of Hsp70 fewer oligomers are detected and fibrillisation is inhibited in a dose dependent manner. In more detail, more medium sized oligomers (6-20mers) and fewer small sized oligomers (2-5mers) are found in presence of the chaperone.
These effects were observed in absence of nucleotides and were found to be abrogated in the presence of ADP or ATP.

Conclusions

Hsp70 interacts with Δ280K tau oligomers to slow down the rapid fibrillisation of the amyloid protein. This inhibitory effect seems to be due to preferential stabilization of medium sized oligomers and occurs in the absence of nucleotides.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Literatur
1.
Zurück zum Zitat Li H, Ying L, Green JJ, Balasubramanian S, Klenerman D: Ultrasensitive Coincidence Fluorescence Detection of Single DNA Molecules. Anal Chem. 2003, 75: 1664-1670. 10.1021/ac026367z.CrossRefPubMed Li H, Ying L, Green JJ, Balasubramanian S, Klenerman D: Ultrasensitive Coincidence Fluorescence Detection of Single DNA Molecules. Anal Chem. 2003, 75: 1664-1670. 10.1021/ac026367z.CrossRefPubMed
2.
Zurück zum Zitat Orte A, Birkett NR, Clarke RW, Devlin GL, Dobson CM, Klenerman D: Direct characterization of amyloidogenic oligomers by single-molecule fluorescence. Proc Natl Acad Sci. 2008, 105: 14424-14429. 10.1073/pnas.0803086105.PubMedCentralCrossRefPubMed Orte A, Birkett NR, Clarke RW, Devlin GL, Dobson CM, Klenerman D: Direct characterization of amyloidogenic oligomers by single-molecule fluorescence. Proc Natl Acad Sci. 2008, 105: 14424-14429. 10.1073/pnas.0803086105.PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Horrocks MH, Li H, Shim J-U, Ranasinghe RT, Clarke RW, Huck WTS, Abell C, Klenerman D: Single molecule fluorescence under conditions of fast flow. Anal Chem. 2012, 84: 179-185. 10.1021/ac202313d.CrossRefPubMed Horrocks MH, Li H, Shim J-U, Ranasinghe RT, Clarke RW, Huck WTS, Abell C, Klenerman D: Single molecule fluorescence under conditions of fast flow. Anal Chem. 2012, 84: 179-185. 10.1021/ac202313d.CrossRefPubMed
Metadaten
Titel
Tau-Hsp70 interaction on the single molecule level
verfasst von
Franziska Kundel
Magnus Kjaergaard
Sarah Shammas
Sophie Jackson
David Klenerman
Publikationsdatum
01.09.2013
Verlag
BioMed Central
Erschienen in
Molecular Neurodegeneration / Ausgabe Sonderheft 1/2013
Elektronische ISSN: 1750-1326
DOI
https://doi.org/10.1186/1750-1326-8-S1-P61

Weitere Artikel der Sonderheft 1/2013

Molecular Neurodegeneration 1/2013 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.